Wegovy demand surges 23% monthly in France post-reimbursement launch
Wegovy sales volume surges 23% monthly following France's reimbursement coverage launch.
Event / Health
France GLP-1 Obesity Medication Reimbursement
French health insurance system began reimbursing GLP-1 obesity medications Wegovy and Mounjaro at 65% coverage for eligible patients through specialized obesity centers, with an estimated annual cost of 100 million euros by 2027.
1 reported locations
Daily activity
0 articles0 articles
2026-08-16 to 2026-11-13 · UTC publication dates
Coverage begins 14 Jun, 11:37 UTC
Follow the documented timeline or explore the related reporting.
What happened
Wegovy sales volume increased 23% monthly since October 2024 launch
Since the launch of Wegovy in October 2024, monthly box sales increased by 23%. The obesity medication market in France had grown to over 150 million euros within eighteen months of launch, representing more than a 20-fold increase from 2024 values.
France begins reimbursement of GLP-1 obesity medications Wegovy and Mounjaro
French health insurance (Assurance Maladie) began reimbursing the GLP-1 medications Wegovy and Mounjaro at 65% coverage for patients with severe obesity or severe obesity with comorbidities. Only specialized obesity centers (CSO) physicians can issue initial prescriptions for these injectable medications, which must be accompanied by secured prescriptions and treatment authorization forms.
French Health Ministry estimates 100 million euro annual cost for obesity drug reimbursement by 2027
The French Health Ministry projected total spending of 100 million euros for obesity drug reimbursement through the Assurance Maladie in 2027, with approximately one million people potentially eligible for the program.
GLP-1 medication prices standardized across French pharmacies
Starting with the reimbursement implementation, all GLP-1 medication prices became identical across French pharmacies, whereas previously prices varied by pharmacy location.
Read the coverage
2 alternative perspectives
France launches reimbursement program for GLP-1 obesity medications
France begins reimbursing GLP-1 obesity drugs with standardized pricing; projected 100 million euro annual cost by 2027.